ROIV Stock Forecast: Roivant Sciences Ltd. Price Predictions for 2026-2027
The 13 Wall Street analysts covering Roivant Sciences Ltd. hold a median 12-month price target of $51 — +32.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 83 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Roivant Sciences Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Quality (35): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ROIV stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ROIV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +32.0% from it.
Of the 20 most recent actions, 13 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2026 | Guggenheim | Maintains | Buy | $46 → $48 |
| 10 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $47 → $48 |
| 28 Oct 2026 | Citigroup | Maintains | Buy | $46 → $56 |
| 12 Oct 2026 | Wolfe Research | Downgrade | Peer Perform | — |
| 17 Sept 2026 | Stifel | Initiates | Buy | $51 |
| 9 Sept 2026 | Guggenheim | Maintains | Buy | $42 → $46 |
| 9 Sept 2026 | TD Cowen | Maintains | Buy | $50 → $55 |
| 8 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $41 → $47 |
| 8 Sept 2026 | Jefferies | Maintains | Buy | $42 → $52 |
| 28 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $41 |
| 10 Aug 2026 | Citigroup | Maintains | Buy | $42 → $46 |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $36 → $42 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $34 → $41 |
| 26 May 2026 | Guggenheim | Maintains | Buy | $30 → $36 |
| 21 May 2026 | Citigroup | Maintains | Buy | $35 → $42 |
| 21 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $34 |
| 21 May 2026 | TD Cowen | Maintains | Buy | $38 → $41 |
| 16 Apr 2026 | Piper Sandler | Maintains | Overweight | — |
| 4 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Feb 2026 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ROIV.
This page is one stock. Monday covers all of them.
ROIV appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ROIV vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Roivant Sciences Ltd. returned +90.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ROIV analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 681.8×
- Price / book
- 7.0×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
Cheaper than 12% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 80.3%
- Operating margin
- —
- Net margin
- —
Higher than 91% of US stocks
- Return on equity
- −8.5%
- Return on assets
- −16.5%
- Dividend yield
- —
Higher than 37% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Roivant Sciences Ltd. has a market value of $28.0B and an enterprise value of $24.5B.
Revenue in the twelve months to 30 June 2026: $7.5M. The latest quarter shrank 33.5% year on year.
Net income over the same four quarters: −$414.6M, a −5504.5% net margin.
Diluted earnings per share, trailing twelve months: −$0.53.
Free cash flow in the twelve months to 30 June 2026: −$821.1M.
Roivant Sciences Ltd. spent $317.9M on share buybacks in the twelve months to 30 June 2026.
Roivant Sciences Ltd. employs 721 people — $10K of revenue per employee.
Data provided by Twelve Data
ROIV and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ROIV’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Roivant Sciences Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ROIV
What is the ROIV stock price forecast for 2026-2027?
The 13 Wall Street analysts covering Roivant Sciences Ltd. have a median 12-month price target of $51, with estimates ranging from $42 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ROIV stock a buy right now?
Of the 13 analysts covering Roivant Sciences Ltd., 11 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Roivant Sciences Ltd. 83 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ROIV?
As at 21 Nov 2026, Roivant Sciences Ltd. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
Will ROIV stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts implies +32.0% from the last close, and Ticker Nerd's factor model ranks Roivant Sciences Ltd. 83 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ROIV stock forecast for 2030?
No analyst covering Roivant Sciences Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ROIV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $42 to $62 over the next 12 months.
How has ROIV stock performed over the past year?
Roivant Sciences Ltd. returned +90.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Roivant Sciences Ltd. do?
Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies through a portfolio of specialized subsidiary companies. Roivant Sciences Ltd. operates across immunology, dermatology, and other high-unmet-need therapeutic areas, with current work spanning commercial products and clinical-stage candidates.
About Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies through a portfolio of specialized subsidiary companies. Roivant Sciences Ltd. operates across immunology, dermatology, and other high-unmet-need therapeutic areas, with current work spanning commercial products and clinical-stage candidates. Its business model emphasizes creating focused operating companies to advance individual drug programs, support partnering activities, and incubate complementary health technology initiatives. The company’s current product and pipeline portfolio includes therapies for autoimmune and inflammatory diseases, as well as treatments being studied in areas such as dermatologic conditions, uveitis, pulmonary hypertension, and rare diseases. Roivant Sciences Ltd. plays a distinctive role in the healthcare market by combining drug development expertise with an asset-centric structure designed to move promising medicines toward commercialization.
CEO Mr. Matthew Gline · 721 employees · United Kingdom · https://roivant.com